NeuroSense Therapeutics (NRSN) Research & Development (2021 - 2024)
NeuroSense Therapeutics (NRSN) posted Research & Development of $10.3 million for Q4 2024, up 223.55% sequentially from -$8.3 million in Q3 2024, and down 18.45% YoY from $12.6 million in Q1 2024.
NeuroSense Therapeutics (NRSN) Research & Development (2021 - 2024) Analysis & Trends
NeuroSense Therapeutics has reported Research & Development for 4 years, with the latest figure at $10.3 million in Q4 2024.
- Quarterly Research & Development fell 18.45% year-over-year to $10.3 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $5.7 million (down 21.67% YoY) and the FY2025 annual result came in at $6.2 million, up 9.28% from the prior year.
- Research & Development improved to $10.3 million in Q4 2024 per NRSN's latest filing, from -$8.3 million in the prior quarter.
- Over five years, Research & Development peaked at $12.6 million in Q4 2023 and troughed at -$8.3 million in Q3 2024.
- A 4-year average of $1.2 million and a median of -$1.0 million in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2024: Research & Development soared 1868.11% in 2023, then tumbled 435.62% in 2024.
- Over 4 years, Research & Development stood at $4.4 million in 2021, then plunged by 116.14% to -$715000.0 in 2022, then jumped by 1868.11% to $12.6 million in 2023, then retreated by 18.45% to $10.3 million in 2024.
- According to Business Quant data, Research & Development over the past three periods registered $10.3 million, -$8.3 million, and $5.6 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 10.31 Mn |
| Sep 30, 2024 | -8.35 Mn |
| Jun 30, 2024 | 5.62 Mn |
| Mar 31, 2024 | -1.88 Mn |
| Dec 31, 2023 | 12.64 Mn |
| Sep 30, 2023 | -1.56 Mn |
| Jun 30, 2023 | -1.96 Mn |
| Mar 31, 2023 | -1.85 Mn |
| Dec 31, 2022 | -715,000.00 |
| Sep 30, 2022 | -8.04 Mn |
| Jun 30, 2022 | 4.46 Mn |
| Mar 31, 2022 | -1.30 Mn |
| Dec 31, 2021 | 4.43 Mn |
| Jun 30, 2021 | 4.54 Mn |